西妥昔单抗联合FOLFIRI治疗转移性结肠癌的临床观察

Clinical observation of cetuximab combined with FOLFIRI in the treatment of metastatic colorectal cancer

目的:探讨西妥昔单抗联合FOLFIRI治疗转移性结肠癌的效果和不良反应。方法:收治转移性结肠腺癌患者10例,给予西妥昔单抗联合FOLFIRI治疗。结果:有效率20%,疾病控制率80%。中位疾病进展时间(TTP)9.7周,中位生存时间(MST)42周。1例出现严重过敏反应,10例患者出现痤疮样皮疹。结论:西妥昔单抗联合FOLFIRI治疗转移性结肠癌有更高的反应率。

Objective:To investigate the curative effect and adverse reactions of cetuximab combined with FOLFIRI in thetreatment of metastatic colorectal cancer.Methods:10 cases of patients with metastatic colorectal cancer were treated withcetuximab combined with FOLFIRI.Results:The effective rate was 20%,and the disease control rate was 80%.The median time oftumor progression was 9.7 weeks and the median survival time (MST) was 42 weeks.1 cases had severe allergic reaction,10 casesof patients had acne-like rash.Conclusion:Cetuximab combined with FOLFIRI in the treatment of metastatic colorectal cancerhad higher response rate.